H.B. Fuller heads into its September 23 report with a strange disconnect between its operating trajectory and its stock chart. The last earnings call described a company moving from defense to offense, with pricing finally sticking, margins expanding, and guidance raised for a second straight quarter. Yet the shares have fallen 17% since that report while the S&P 500 climbed 3%, a 20 point relative gap that suggests the market is more worried about what comes next than reassured by what already happened. This report needs to answer which narrative is closer to the truth.

Consensus calls for EPS of $1.46 on revenue of $940.4 million, which would represent 15.9% earnings growth and 5.4% revenue growth year over year. The whisper number sits just a penny below consensus at $1.45, a gap too small to read as a meaningful signal either way, but the broader sentiment shift is notable. Bullish sentiment ahead of the prior report was 28%, and it has now flipped to 14.2% bearish. That swing matters more than the point estimates themselves, because it shows expectations have cooled even as the company's own guidance has not.

Management's full year outlook, narrowed to $4.60 to $4.90 in EPS with revenue still pegged around $3.65 billion, keeps the Street's $4.78 estimate comfortably inside the range, closer to the midpoint than either extreme. That is a reasonable place for consensus to sit, but it also means there is little room for the company to simply coast. The bar was already raised twice this fiscal year, first from $4.55 to $4.90 and now tightened again, so continued confidence requires evidence that the pricing gains flagged last quarter are still compounding rather than plateauing.

The most important thread to pull on is the gap between pricing strength and volume weakness. Last quarter, run-rate pricing hit roughly 6% by May with management pointing to high single digit pricing for the second half, while organic growth swung positive after a rough first quarter. But volumes were still guided down mid-single digits for the second half, essentially unchanged from the prior quarter's assumption, and automotive turned negative across all three regions. Investors should want to see whether pricing actually offset that volume drag as promised, particularly in Hygiene, Health and Consumables, where margin already jumped 230 basis points last quarter on pricing execution. If HHC margin continues climbing while automotive and other end markets stay soft, that would validate the idea that Fuller is successfully passing through costs rather than merely riding a temporary tailwind.

Raw material inflation is the other swing factor. With roughly 90% of raw materials running higher than the prior quarter and 52 force majeures still active, management has been clear that costs are not expected to retrace to pre-disruption levels. This report should show whether the company is staying ahead of that inflation through pricing or whether the gap is widening, which would pressure margins even if pricing headlines look strong.

Finally, the market has not forgotten the roughly 715 million pound AMS acquisition announced last quarter, which pushed pro forma leverage toward 4x, well above the company's 2.5 to 3.0x target, and triggered an 8 to 10% stock decline at the time. With shares now trading at $50.97, below the 200-day average of $59.98 and near the low end of the post-earnings range between $50.76 and $64.52, the stock is behaving as if investors remain unconvinced the leverage tradeoff was worth it. Commentary on integration progress, synergy timing, and any update on deleveraging will likely matter as much as the headline numbers. The central question heading into this report is whether Fuller can show that its pricing led margin recovery is durable enough to justify the leverage it just took on, or whether persistent volume softness and raw material pressure will reopen doubts about the turnaround story management laid out last quarter.